Atrial Fibrillation, Coronary Artery Disease
Conditions
Brief summary
We investigated in-vitro the management of intraprocedural anticoagulation in patients requiring immediate percutaneous coronary intervention(PCI) while using regular direct oral anticoagulants(DOACs). Twenty-five patients taking 20mg of rivaroxaban once daily comprised the study group, while five healthy volunteers included the control group. In study group, a beginning(24-hours after the last rivaroxaban dose) examination was performed. Then, the effects of basal and four different anticoagulant doses(50IU/kg unfractionated heparin(UFH), 100IU/kg UFH, 0.5mg/kg enoxaparin, and 1mg/kg enoxaparin) on coagulation parameters were investigated at the 4th and 12th hours following rivaroxaban intake. Anticoagulant activity was assessed mainly by anti-factor Xa(anti-Xa) levels.
Interventions
DRUGIn vitro heparin
In vitro heparin and in vitro LMWH
Sponsors
Bursa Postgraduate Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 74 Years
Inclusion criteria
* patients using the direct oral factor Xa inhibitor rivaroxaban * Atrial fibrillation
Exclusion criteria
* malignancy, * coagulopathy, * heart valve disease, * active infection, * chronic systemic or inflammatory disease, * recent ACS or elective PCI, * uncontrolled hypertension and diabetes, * cerebrovascular accident, * thyroid disorder, * left ventricular systolic dysfunction (ejection fraction \<50%), * glomerular filtration rate \<50 mL/min/1.73 m2, * underweight and overweight (\<60 kg and \>100 kg), * age \>75 years, * hyperbilirubinemia and hypertriglyceridemia (\>350 mg/dl).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anticoagulation level | 4 - 12 hours | anti-factor Xa |
Countries
Turkey (Türkiye)
Outcome results
None listed